Survival outcomes in POD1UM-303/InterAACT-2: a phase 3 study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

Key Points

• This research aims to evaluate the survival outcomes of retifanlimab combined with carboplatin and paclitaxel in patients with first-line advanced squamous anal cancer.
• Phase 3 trial design
• Participants received retifanlimab plus carboplatin and paclitaxel
• Study conducted globally, including Australia.
• The combination therapy improved overall survival rates in the treatment group compared to historical controls.
• Exact survival metrics and statistical significance were not provided in the abstract.